Detection and clinical relevanc ...
The factors determining the clinical relevance of disseminated tumor cells (DTC) in breast cancer patients are largely unknown. Here we compared the ...
Clinical potential of the mTOR ...
The mammalian target of rapamycin (mTOR) and its substrates S6K1 and S6K2 regulate cell growth, proliferation, and metabolism through translational ...
Bone mineral density and risk o ...
To determine if higher bone mineral density (BMD) is a risk factor for breast cancer in women age 50 years and older. 37,860 women C50-year old with ...
Phase I trial of oral mTOR inhi ...
To determine the feasible dose and schedule for everolimus, an oral mTOR inhibitor, combined with vinorelbine and trastuzumab for patients with HER2 ...
A gene expression signature ide ...
Prognosis of basal breast cancers is poor but heterogeneous. Medullary breast cancers (MBC) display a basal profile, but a favorable prognosis. We h ...
Oncologic safety of breast cons ...
The objective of this study is to analyse local recurrence rates in patients receiving neoadjuvant chemotherapy (nCT) comparing mastecomized (MX) pa ...
Pure flat epithelial atypia (DI ...
Flat epithelial atypia (FEA) is recognized as a precursor of breast cancer and its management (surgical excision or intensive follow-up) remains unc ...
Coexpression of atypical chemok ...
Some evidence suggests that atypical chemokine binders (ACBs) including DARC, D6, and CCX-CKR play an important role in inhibiting invasion and meta ...
Proliferating macrophages assoc ...
Macrophages, a key cell in the inflammatory cascade, have been associated with poor prognosis in cancers, including breast cancer. In this study, we ...
Family history of breast cancer ...
Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers of mutations in BR ...
The impact of an aromatase inhi ...
Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailab ...
Nuclear and cytoplasmic express ...
Estrogen receptor (ER) a has been studied extensively in familial breast cancers but there are limited data on ERb and its isoforms. This is an impo ...
Adjuvant dose-dense doxorubicin ...
Every-2-week (dose-dense) adjuvant doxorubicin (A) plus cyclophosphamide (C) followed by paclitaxel is a safe and effective adjuvant chemotherapy re ...
S-adenosylhomocysteine hydrolas ...
Epigenetic abnormalities including abnormal histone methyltransferase activity contribute to breast cancer pathogenesis. An example is over expressi ...
Comparison of different approac ...
Human epidermal growth factor receptor 2 (HER2) testing is an essential part of pathological assessment in breast cancer patients, as HER2 provides ...
An evaluation of the clinical s ...
Studies in mice have shown that thymicderived CD4? CD25? regulatory T cells (T reg; FOXP3? lymphocytes) inhibit an antitumour immune response. Addi ...
Involvement of MyoD and c-myb i ...
BRCA1 is closely related to the pathogenesis of breast cancer, BRCA1 mRNA is reduced in sporadic breast cancer cells despite the lack of mutations. ...
Anti-tissue factor short hairpi ...
In breast cancer, there is a correlation between tissue factor (TF) expression, angiogenesis and disease progression. TF stimulates tumour angiogene ...
Association between mitogen-act ...
Published data on the association between mitogen-activated protein kinase kinase kinase 1 (MAP3K1) gene rs889312 polymorphism and breast cancer ris ...
Association of age and overall ...
We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC). Pooled ana ...
Estrogen receptor beta decrease ...
Estrogen receptor beta (ERb) inhibits proliferation in different cellular systems by regulating components of the cell cycle machinery. Eukaryotic c ...
CD4+ T cells inhibit the neu-sp ...
Studies conducted in animal model of infectious diseases or H-Y antigen model suggest a crucial role for CD4? T cells in providing help for CD8? T-c ...
High serum TGF-a predicts poor ...
Lapatinib and capecitabine combination therapy is effective in trastuzumab-resistant human epidermal growth factor receptor 2 (HER2)-positive breast ...
Results of a phase II study of ...
Palliation is the primary goal in metastatic breast cancer (MBC), and safe, efficacious, new singleagent options are needed. Pemetrexed, an antifola ...
Zoledronic acid prevents bone l ...
To determine whether zoledronic acid (ZA) can prevent bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer. In this r ...